Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model
{{output}}
Recent studies have explored combining MDM2 antagonists with immunotherapy. Here, we assessed the effect of anti-PD-1 and idasanutlin co-treatment in a syngeneic CT26/BALB/c mouse model. Prior to in vivo testing, idasanutlin's activity was evaluated in three ... ...
